BG108379A - Използване на енантиомерно чист есциталопрам - Google Patents

Използване на енантиомерно чист есциталопрам Download PDF

Info

Publication number
BG108379A
BG108379A BG108379A BG10837903A BG108379A BG 108379 A BG108379 A BG 108379A BG 108379 A BG108379 A BG 108379A BG 10837903 A BG10837903 A BG 10837903A BG 108379 A BG108379 A BG 108379A
Authority
BG
Bulgaria
Prior art keywords
escitalopram
treatment
pharmaceutical composition
disorder
disorders
Prior art date
Application number
BG108379A
Other languages
Bulgarian (bg)
English (en)
Inventor
Connie Sanchez
Jensen Jesper Lyng
Arne Mork
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of BG108379A publication Critical patent/BG108379A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG108379A 2001-05-01 2003-11-24 Използване на енантиомерно чист есциталопрам BG108379A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01

Publications (1)

Publication Number Publication Date
BG108379A true BG108379A (bg) 2004-11-30

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108379A BG108379A (bg) 2001-05-01 2003-11-24 Използване на енантиомерно чист есциталопрам

Country Status (25)

Country Link
US (7) US20040198809A1 (no)
EP (1) EP1385503A1 (no)
JP (1) JP2004527551A (no)
KR (2) KR20100012089A (no)
CN (1) CN1509169A (no)
AR (1) AR033308A1 (no)
AT (1) AT10974U1 (no)
BG (1) BG108379A (no)
BR (1) BR0208283A (no)
CA (1) CA2445843A1 (no)
CZ (1) CZ20033267A3 (no)
EA (1) EA200301195A1 (no)
HR (1) HRP20030744A2 (no)
HU (1) HUP0400054A3 (no)
IL (1) IL158031A0 (no)
IS (1) IS6954A (no)
ME (1) MEP5908A (no)
MX (1) MXPA03008777A (no)
NO (1) NO20034538D0 (no)
PL (1) PL367480A1 (no)
SK (1) SK14612003A3 (no)
UA (1) UA82828C2 (no)
WO (1) WO2002087566A1 (no)
YU (1) YU85303A (no)
ZA (1) ZA200307102B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
KR20100012089A (ko) * 2001-05-01 2010-02-05 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도
RS51092B (sr) * 2002-12-23 2010-10-31 H. Lundbeck A/S. Escitalopram bromhidrat i postupak za njegovo pripremanje
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
BRPI0508266A (pt) * 2004-03-05 2007-07-31 Lundbeck & Co As H partìculas cristalinas de oxalato de escitalopram, forma de dosagem única sólida, e, métodos para a fabricação de partìculas cristalinas de oxalato de escitalopram e para reduzir a quantidade de hidroxila que contém impurezas no citalopram, escitalopram ou uma mistura não racêmica de r- e s-citalopram
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
CN101374507A (zh) * 2005-10-14 2009-02-25 H.隆德贝克有限公司 含有依他普仑和安非他酮的稳定药物制剂
EA200801081A1 (ru) 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
WO2008046617A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
JP5404048B2 (ja) * 2006-10-27 2014-01-29 久光製薬株式会社 貼付剤
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
WO2009020897A1 (en) * 2007-08-03 2009-02-12 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
CA2713598C (en) * 2008-01-31 2016-07-05 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
US10702512B2 (en) * 2015-05-13 2020-07-07 A. Carlsson Research Ab Treatment of debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (no) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EA002770B1 (ru) * 1997-11-11 2002-08-29 Х.Лундбекк А/С Способ получения циталопрама
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
NZ510858A (en) * 1998-10-20 2003-11-28 H Method for the preparation of citalopram
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
KR20100012089A (ko) * 2001-05-01 2010-02-05 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도

Also Published As

Publication number Publication date
UA82828C2 (en) 2008-05-26
US20040198811A1 (en) 2004-10-07
KR20040030609A (ko) 2004-04-09
IL158031A0 (en) 2004-03-28
US20040198810A1 (en) 2004-10-07
HRP20030744A2 (en) 2005-06-30
MXPA03008777A (es) 2004-02-12
MEP5908A (xx) 2010-02-10
EA200301195A1 (ru) 2004-04-29
SK14612003A3 (sk) 2004-04-06
WO2002087566A1 (en) 2002-11-07
CZ20033267A3 (en) 2004-06-16
YU85303A (sh) 2006-05-25
CA2445843A1 (en) 2002-11-07
HUP0400054A3 (en) 2007-03-28
JP2004527551A (ja) 2004-09-09
CN1509169A (zh) 2004-06-30
HUP0400054A2 (hu) 2004-04-28
AR033308A1 (es) 2003-12-10
US20080004338A1 (en) 2008-01-03
US20040192766A1 (en) 2004-09-30
US20040198809A1 (en) 2004-10-07
PL367480A1 (en) 2005-02-21
US20040192765A1 (en) 2004-09-30
EP1385503A1 (en) 2004-02-04
AT10974U1 (de) 2010-02-15
IS6954A (is) 2003-09-15
BR0208283A (pt) 2004-03-09
ZA200307102B (en) 2004-09-13
NO20034538L (no) 2003-10-09
US20040192764A1 (en) 2004-09-30
KR20100012089A (ko) 2010-02-05
NO20034538D0 (no) 2003-10-09

Similar Documents

Publication Publication Date Title
BG108379A (bg) Използване на енантиомерно чист есциталопрам
Akhondzadeh et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial
Outfitters et al. Revisiting monoamine oxidase inhibitors
BRPI0610509A2 (pt) tratamento de dependência a drogas
HU208484B (en) Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
WO2020041329A1 (en) Combination therapy for treating or preventing depression or other mood diseases
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
CN114727989A (zh) Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合
JP2005513105A (ja) 臨床的うつ病を治療するためのデオキシペガニンの使用
Tariot et al. Treating Alzheimer's disease: pharmacologic options now and in the near future
AU2002254870A1 (en) The use of enantiomeric pure escitalopram
KR20010099648A (ko) 신규 조성물
AU2008201217A1 (en) The use of enantiomeric pure escitalopram
US20150335649A1 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
WO2002076461A1 (en) Combination of reboxetine and citalopram
JP2009545573A (ja) サレデュタントとおよびセロトニン再取込みの選択的阻害剤またはセロトニン／ノルエピネフリン再取込みの阻害剤とを組み合わせて含有する医薬組成物
HRP20100463A2 (hr) Upotreba čistog enantiomernog citaloprama
KR101736846B1 (ko) 급성관동맥증후군에 동반되는 우울증 치료용 약제학적 조성물
US20050101666A1 (en) Method of treating premenstrual dysphoric disorder with escitalopram
WO2023236781A1 (zh) 治疗精神类疾病的方法
KR20140069120A (ko) S1p 수용체 조절제를 포함하는 조합물
De Clercq et al. P01. 41 Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatment
Reynaert et al. P01. 40 Efficacy of venlafaxine in depressed patients after switching from prior SSRI treatment
CA2975571A1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
Dodd et al. Duloxetine for major depression